reference/380793

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/380793

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Research Support, N.I.H., Extramural
endingPage	198
issn	1527-7755 0732-183X
issueIdentifier	2
pageRange	193-198
publicationName	Journal of clinical oncology : official journal of the American Society of Clinical Oncology
startingPage	193
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_5644ac74d485a2a0d8cb672bfb7166b0 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_02c3c8e5efba91bb7bcd17f31040a5fe http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_57fe80ecb0f252f4567e58a36d905754 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_6f29fdedd9509febabd2e8b977bd5bd3 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_fd3f2b003fcbb54c8fee2987642dcaca
bibliographicCitation	Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP, Fuchs CS. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009 Jan 10;27(2):193–8. PMID: 19047305; PMCID: PMC2645085.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_45efdb864e1eb4e86e43b9f9c10cfe7e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e42c41d11e2e4e9e85ca4227b1b51082 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d6ebb0c488dde33e9c3306aec97f04ec http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d5c88a98040e677422c1ad7417cff02e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_43efb2b1ff774ae043c6aacb469e8b82 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b0f2621a015d3a4236764c6a75a4f6c9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_af3616f1b6067f9d8212ce593df9db53 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_96b094a773b26932518f188253b418a6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2a09b6fbf10e1322b1a28ad933e5f2e1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4c2fc83dcb215e4d34c3967e2249a134 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ec92f82ea5433b864e911fef6b1eb5a5
date	2009-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/19047305 https://pubmed.ncbi.nlm.nih.gov/PMC2645085 https://doi.org/10.1200/jco.2008.18.9514
isPartOf	https://portal.issn.org/resource/ISSN/1527-7755 https://portal.issn.org/resource/ISSN/0732-183X http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5023
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
discusses	http://id.nlm.nih.gov/mesh/M000649677 http://id.nlm.nih.gov/mesh/M0469193 http://id.nlm.nih.gov/mesh/M0017869 http://id.nlm.nih.gov/mesh/M0150731 http://id.nlm.nih.gov/mesh/M000602394 http://id.nlm.nih.gov/mesh/M0543256 http://id.nlm.nih.gov/mesh/M0029863 http://id.nlm.nih.gov/mesh/M000754277 http://id.nlm.nih.gov/mesh/M0005997
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D010190Q000188 http://id.nlm.nih.gov/mesh/D011494Q000378 http://id.nlm.nih.gov/mesh/D020123Q000031
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D019008 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D015398Q000187 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000093542 http://id.nlm.nih.gov/mesh/D019869Q000378 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D020123Q000009 http://id.nlm.nih.gov/mesh/D003841Q000494 http://id.nlm.nih.gov/mesh/D003841Q000031 http://id.nlm.nih.gov/mesh/D000081082 http://id.nlm.nih.gov/mesh/D051058Q000378 http://id.nlm.nih.gov/mesh/D010190Q000378 http://id.nlm.nih.gov/mesh/D051058Q000037 http://id.nlm.nih.gov/mesh/D000284 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D058570 http://id.nlm.nih.gov/mesh/D020123Q000627 http://id.nlm.nih.gov/mesh/D000068338
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_472b28cee6c37ce9d58de4aa1dc6d7ef http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID643993 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_d0bb789479d34dbc0811f92fc2bc5049 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6442177 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60750 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_c7be83279551b50c0e81dc2dbfe3c5d8 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3385 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fe0d872c4ea3e7d9f07488fc82841cc8 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9408 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8766 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8072

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129221764 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID248766214 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127639621 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID242749350 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127952853 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128132375

Total number of triples: 89.